Get started

Approval

ETH Bullish Pennant | ETF approval confluence | Target: 2021 ATHNot Financial Advice TL;DR Bullish Pennant on BINANCE:ETHUSDT daily chart, upwards breakout target would be very close to 2021 ATH. SEC approval of VanEck ETF (final deadline on May 23) could be a major catalyst. A rare case of (potential) technical and fundamental confluence: ETH has been building a Bullish Pennant since the end of the Feb 5 - Mar 12 rally The retest of the multi-month support in place since October 2023 might signal that the bottom is in The final deadline for SEC's approval of VanEck's ETH ETF lines up almost perfectly with the convergence between the pennant's resistance and the multi-month support Interestingly enough, the target for an upwards breakout of the pennant around VanEck's approval deadline would be very close to the 2021 ATH
Long
by AliferCrypto
3
ETH - Critical Zone 👀 Again!Hello TradingView Family / Fellow Traders, As per my last analysis, ETH rejected the $3000 support and traded higher. What's next? Scenarios: 1️⃣ Bullish - Continuation For the bulls to maintain control, a break above the $4,000 - $4,100 is needed. In this case, a movement towards the $4,500 resistance would be expected. 2️⃣ Bearish - Correction Meanwhile, the bears can still kick in for a correction towards $3,500 where we will be looking for new short-term buy setups. Which scenario is more likely to happen first? and why? 📚 Always follow your trading plan regarding entry, risk management, and trade management. Good luck! All Strategies Are Good; If Managed Properly! ~Richard Nasr
by TheSignalyst
22
ETH Ethereum Price Prediction after the BTC ETF approvalThe price of Ethereum (ETH) will be affected by the approval of the Bitcoin ETF this week. Some of the biggest asset managers on the entire planet are going to release a BTC ETF: Blackrock $9.3 Trillion Fidelity $4.5 Trillion Franklin Templeton $1.53 trillion Invesco $1.5 Trillion. BlackRock expects Bitcoin ETF approval on Wednesday, in-line with Bloomberg's January 10 deadline. I expect the approval to a buy the rumor, sell the news event. Employing the strategy of "buy the rumor, sell the news," traders strategically capitalize on market movements by entering positions based on speculative information. This approach involves opening positions on rumors and closing them when the anticipated news is officially announced, typically resulting in a profit. A retracement in the price of Ethereum, after the news, probably to $1900, would be a buying opportunity for a year-end rally, in my opinion.
by TopgOptions
We Have Our Answer!Traders, A few posts ago, you will see that (2) two gaps were being focused on. The question was posed about which might be filled first. Many of my followers understand that my bias was to the upside gap being filled first. Thanks to the Blackrock ETF approval, this has occurred. And, as I stated in my video yesterday, I have unloaded 50% of ALL my positions (alts included), taken profits, and moved my stops up to break even. I will let the remainder ride for now and hopefully take the rest off at the 50 day ma of the SPOT BTC chart which intersect exactly with the bottom of that important support (now resistance) which I talked about in yesterday's video at 28,750. If we don't hit that and I get stopped out instead, no issue cuz I move all my stops to break even and will take no loss now. There still remain (2) two unfilled gaps: one at 20,290 from March of this year and one at 35,180 from May of last year. I still believe both will be filled soon. Stay tuned for more on this unfolding price action as, through charting research, I hope to gain a better grasp on how it will go. Stew
CME:BTC1!Long
by stewdamus
$BPTH Posts Positive Phase 2 Trials for Leukemia DrugBio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration. Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in conjunction with the low-dose chemotherapy regimen cytarabine in 17 newly diagnosed AML patients revealed that the proportion of patients showing a response increased from 47 percent when assessed in April 2018 to 65 percent. Of the patients showing a response, 5, or 29 percent, showed a complete response compared to the benchmarked percentage of 7-13 percent. AML: A Cancer Of Blood Cells: AML is a form of blood cancer that develops in the bone marrow, where blood cells originate. It afflicts a group of white blood cells called myeloid cells that develop into mature blood cells such as red blood cells, white blood cells and platelets. A patient with AML will see rapid accumulation of immature myeloid cells in the blood, resulting in a drop of other blood cell types. BP1001's Mode Of Action: Prexigebersen is a neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of growth factor receptor bound protein 2, or Grb2. Grb2 has a role to play in cancer cell activation via the RAS pathway. Inhibition of Grb2 is found to halt cell proliferation and enhance cell killing by chemotherapeutic agents without added toxicity. A Lucrative Market: AML accounts for roughly 36 percent of all leukemias, with about 20,000 new cases diagnosed each year, Bio-Path said, citing National Cancer Institute estimates. A critically unmet need exists for non-toxic therapies for older, fragile AML patients who are unfit or ineligible for high-dose chemotherapy or a stem cell transplant. What's Next: Bio-Path said it believes it now has a plan with definable paths to registration. It plans to amend the Stage 2 prexigebersen + decitabine Phase 2 AML cohort in untreated new patients to add untreated high-risk myelodysplastic syndrome, or MDS, patients. The company also intends to cancel the Stage 2 prexigebersen + LDAC Phase 2 AML cohort in untreated de novo patients. It also plans to test a triple combo of prexigebersen + decitabine + venetoclax for untreated AML and high-risk MDS patients in a registration-directed trial to determine if more durable responses and longer survival are observed compared to patients treated with the decitabine + venetoclax combination. The next major catalyst for Bio-Path will be the fourth-quarter results expected sometime in the next month.
NASDAQ:BPTHLong
by StockGuild